Grace Therapeutics, Inc.
GRCE· Nasdaq
GRCEGrace Therapeutics, Inc.
Filed Jun 18, 2026 · 10-K · 79 days after period end · 0001140361-26-025662
derived · Computed from the longer spans the company filed.
| Metric | Q4 2026dderived from reported figures | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$1.18M | $636.00K | -$3.17M | -$29.09M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed Jun 18, 2026 · 79 d after period end
